EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.

Founder’s bold move signals breakout moment for EDX Medical
Renowned biotech entrepreneur Professor Sir Chris Evans leads a £3 million raise for EDX Medical, boosting its cutting-edge prostate cancer test.